The 4 analysts offering 12-month price forecasts for Verrica Pharmaceuticals Inc have a median target of 10.50, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +213.43% increase from the last price of 3.35.
The current consensus among 5 polled investment analysts is to Buy stock in Verrica Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.19
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.